Read by QxMD icon Read

Current Drug Delivery

Heather A E Benson, Jeffrey E Grice, Yousuf Mohammed, Sarika Namjoshi, Michael S Roberts
This overview on skin delivery considers the evolution of the principles of percutaneous absorption and skin products from ancient times to today. Over the ages, it has been recognised that products may be applied to the skin for either local or systemic effects. Major changes have occurred in our understanding of the skin and the sophistication in our technology to effectively and quantitatively deliver solutes across this barrier to specific target sites in the skin and beyond. We focus on these technologies and their role in skin delivery now and in the future...
February 1, 2019: Current Drug Delivery
Afzal Hussain, Sima Singh, Sabya Sachi Das, Keshireddy Anjireddy, Subramanian Karpagam, Faiyaz Shakeel
In spite of advances in tuberculosis (TB) chemotherapy, TB is still air-born deadly disorder as major issue of health concern worldwide today. Extensive researches have been focused to develop novel drug delivery systems to shorten the lengthy therapy approaches, prevention of relapses, reducing dose related toxicities and to rectify technological related drawbacks of anti-tubercular drugs. Moreover, rapid emergence of drug resistance, poor patient compliance due to negative therapeutic outcomes and intracellular survival of Mycobacterium highlighted to develop carrier with optimum effectiveness of the anti-tubercular drugs...
February 1, 2019: Current Drug Delivery
Jieru Yang, Yacheng Luo, Mohini Anjna Shibu, Istvan Toth, Mariusz Skwarczyski
Subunit vaccines are composed of pathogen fragments that, on their own, are generally poorly immunogenic. Therefore, the incorporation of an immunostimulating agent, e.g. adjuvant, into vaccine formulation is required. However, there are only a limited number of licenced adjuvants and their immunostimulating ability is often limited, while their toxicity can be substantial. To overcome these problems, a variety of vaccine delivery systems have been proposed. Most of them are designed to improve the stability of antigen in vivo and its delivery into immune cells...
January 23, 2019: Current Drug Delivery
Divya Thakur, Gurpreet Kaur
BACKGROUND: Over the past century, prevalence of skin diseases has substantially increased. These diseases present a significant physical, emotional and socio-economic burden to the society. Such conditions are also associated with multitude of psychological traumas to the suffering patients. The effective treatment strategy implicates targeting of drugs to skin. The field of drug targeting has been revolutionized with an advent of nanotechnology. The emergence of stimulus responsive nano platforms has provided remarkable control over fundamental polymer properties for external triggers...
January 23, 2019: Current Drug Delivery
Mohammad Nasiri, Amir Azadi, Mohammad Reza Saghatchi Zanjani, Mehrdad Hamidi
As an anti-retroviral protease inhibitor (PI), indinavir (IDV) is part of the regimen known as Highly Active Anti-Retroviral Therapy (HAART) widely used for Human Immunodeficiency Virus (HIV) infection. The drug efficiency in treatment of the brain manifestations of HIV is, however, limited which is mainly due to the efflux by P-glycoprotein (P-gp) expressed at the Blood-Brain Barrier (BBB). To overcome the BBB obstacle, NLCs was attempted in this study as carriers for IDV, which was optimized through two steps: a "one-factor-at-a-time" screening followed by a systematic multi-objective optimization...
January 23, 2019: Current Drug Delivery
Nawzat D Al-Jbour, Mohammad D Beg, Jolius Gumbung, A K M Moshiul Alam
Chitosan is a polycationic natural polymer which is abundant in nature. Chitosan has gained much attention as natural polymer in the biomedical field. The up to date drug delivery as well as the nanotechnology in controlled release of drugs from chitosan nanofibers are focused in this review. Electrospinning is one of the most established and widely used techniques for preparing nanofibers. This method is versatile and efficient for the production of continuous nanofibers. The chitosan-based nanofibers are emerging materials in the arena of biomaterials...
January 23, 2019: Current Drug Delivery
Ting Wen, Boyi Niu, Qiaoli Wu, Yixian Zhou, Xin Pan, Guilan Quan, Chuanbin Wu
BACKGROUND: Fenofibrate (FNB) is an effective drug for the treatment of hypertriglyceridemia, hypercholesterolemia as well as mixed hyperlipidemia. However, due to its poor aqueous solubility, FNB exists the problem of poor oral absorption followed by low bioavailability. OBJECTIVE: The aim of this research was to construct FNB amorphous solid dispersion employing PVP VA64 as the carrier by hot-melt extrusion method, in order to improve the oral bioavailability...
January 22, 2019: Current Drug Delivery
Chiara G M Gennari, Francesca Selmin, Paola Minghetti, Francesco Cilurzo
Medicated foams and film forming systems are dosage forms formulated to undergo to a controlled metamorphosis when applied on the skin. Indeed, due to the presence of propellant or a particular air-spray foam pump, a liquid can generate a foam when applied on the stratum corneum, or a liquid or conventional dosage form can form on the skin a continuous film as a consequence of the solvent evaporation. Thanks to these controlled modifications, the drug thermodynamic activity increases favoring the skin penetration and, therefore, the bioavailability with respect to conventional semi-solid and liquid dosage forms...
January 18, 2019: Current Drug Delivery
Meng Yang, Yongwei Gu, Xiaomeng Tang, Ting Wang, Jiyong Liu
On account of the advantages of transdermal delivery and the application situation of transcutaneous technology in transdermal delivery, the article critically comments nanosystems as permeation enhancement model. Nanosystems possess great potential for transcutaneous drug delivery. This review focuses on recent advances in lipid based nanocarriers, including liposome, transfersomes, ethosomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid carriers and combination application of the lipid based nanocarriers with microneedle, iontophoresis, electroporation and sonophoresis in the field for the development of the transdermal drug delivery system...
January 18, 2019: Current Drug Delivery
Carmen Stavarache, Mircea Vinatoru, Timothy Mason
Capsules containing a dye were prepared by the LbL method with iron oxide nanoparticles (50 nm) in different layers of the shell. The capsules were dispersed in a gel and subjected to focused ultrasonic irradiation at three different powers and exposure times. It was found that the inclusion of iron oxide magnetic nanoparticles in any of the polyelectrolyte shells (4, 6, 8 and 10) strengthened the capsules with respect to capsules without nanoparticles. Incorporation of nanoparticles in shell 8 provided the most resistance to fragmentation under focused ultrasonic irradiation...
January 3, 2019: Current Drug Delivery
Abdelazim Zaghloul, Ahmed Lila, Fathy Abd-Allah, Aly Nada
Self-emulsifying drug delivery system (SEDDS), if taken orally, is expected to self-emulsify in GIT and improve the absorption and bioavailability. Probucol (PB) is a highly lipophilic compound with very low and variable bioavailability. The objectives of this study were to examine the stability and conduct bioavailability of the prepared probucol self-emulsified drug delivery system (PBSEDDS) in human volunteers. The methods included preparation of different PBSEDDS using soybean oil (solvent), Labrafil M1944CS (surfactant) and Capmul MCM-C8 (co-surfactant)...
December 26, 2018: Current Drug Delivery
Mert Ilhan, Fatma Tuğçe Gürağaç, Esra Küpeli Akkol
Endometriosis is a disease in which the lining of the endometrium is found outside of the uterus. Recent medical treatments for endometriosis have adverse effects, limiting their long-term use. Furthermore, the recurrence of the disease after the cessation of therapy is quite common, and most patients need to continue treatment to maintain a hypoestrogenic environment till conception. Notwithstanding recent advances in computational and chemical practices, traditional medicines are considered the most consistent sources for the discovery of new drugs...
December 26, 2018: Current Drug Delivery
Govind Soni, Khushwant S Yadav, M K Gupta
Gefitinib (GEF), the kinase inhibitor, is presently available as tablets to be taken orally in high doses of 250-500 mg per day due to its poor solubility. The solubility issues affect not only its onset of action but also the bioavailability. These drawbacks foresight the need to have an alternate dosage form, preferably a sustained release formulation. In the present study, microparticles were prepared by emulsion solvent evaporation using PLGA 50:50 (GEF-PLGA MP). A 32 factorial design was used to optimize the critical quality parameters to the set mean particle size in the range of 7...
December 26, 2018: Current Drug Delivery
Fahad Pervaiz, Mahmood Ahmad, Ghulam Murtaza
PURPOSE: The Purpose of this study was to develop a new PLGA based microsphere formulation aimed to release the olanzapine for the period of one month which will result in increased compliance. METHODS: Microspheres loaded with olanzapine were prepared using oil in water emulsion and solvent evaporation technique. The microspheres were characterized by surface morphology, shape, size, bulk density, encapsulation efficiency, and Fourier transform infrared spectrometry...
December 26, 2018: Current Drug Delivery
Xing-Jie Liang
No abstract text is available yet for this article.
2019: Current Drug Delivery
Guanbao Li, Pinquan Li, Qiuan Chen, Hnin Ei Thu, Zahid Hussain
BACKGROUND: Owing to their great promise in the spinal surgeries, bone graft substitutes have been widely investigated for their safety and clinical potential. By the current advances in the spinal surgery, an understanding of the precise biological mechanism of each bone graft substitute is mandatory for upholding the induction of solid spinal fusion. OBJECTIVE: The aim of the present review is to critically discuss various surgical implications and level of evidence of most commonly employed bone graft substitutes for spinal fusion...
2019: Current Drug Delivery
Kathleen Halasz, Shannon J Kelly, Muhammad Tajwar Iqbal, Yashwant Pathak, Vijaykumar Sutariya
BACKGROUND: The current treatment of ocular neovascularization requires frequent intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents that cause severe side effects. OBJECTIVE: The purpose of this study is to prepare and characterize a novel nanoscale delivery system of apatinib for ocular neovascularization. METHODS: The optimized formulation showed a particle size of 135.04 nm, polydispersity index (PDI) of 0...
2019: Current Drug Delivery
Marcos Luciano Bruschi
The advances and the impact of nanostructured systems on therapeutics constitute a constantly evolving reality. New strategies have been developed for drug delivery control and for directing these systems to the targeted site improving the therapy. In this commentary, the lectins are briefly reviewed; their fundamentals and the proposed applications as ligands in nanostructured drug delivery systems are discussed.
November 21, 2018: Current Drug Delivery
Pooja MIttal, Harsh Vrdhan, Gufran Ajmal, Gunjan Bonde, Ramit Kapoor, Brahmeshwar Mishra
BACKGROUND: Genistein (Gen) is a naturally occurring soy isoflavonoid, possessing anticancer, antiproliferation & antioxidant-like properties. The disadvantage of poor solubility and less oral bioavailability restrict its use as a potential anticancer agent. OBJECTIVES: The current work was focused on the formulation and characterization of the genistein loaded nanostructured lipid carriers that can entrap enough quantity of the drug which will provide sustained release of the drug for the treatment of ovarian cancer...
November 20, 2018: Current Drug Delivery
Hanmei Li, Yuling Xu, Yuna Tong, Yin Dan, Tingting Zhou, Jiameng He, Shan Liu, Yuxuan Zhu
In this study, an injectable sucrose acetate isobutyrate (SAIB) drug delivery system (SADS) was designed and fabricated for the sustained release of ropivacaine (RP) to prolong the duration local anesthesia. By mixing SAIB, RP, and N-methyl-2-pyrrolidone, the SADS was prepared in a sol state with low viscosity before injection. After subcutaneous injection, the pre-gel solution underwent gelation in situ to form a drug-released depot. The in vitro release profiles and in vivo pharmacokinetic analysis indicated that RP-SADS had suitable controlled release properties...
November 18, 2018: Current Drug Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"